Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide. Newsome SD, Mokliatchouk O, Castrillo-Viguera C, Naylor ML. Mult Scler Relat Disord. 2020 Jan 17;40:101954
In a fish tank you have the bottom feeders that clear up the scraps left by others, in this report we have a battle of the bottom feeders, where people have looked at trials and said this is better than that. I would say (a) they should do head to head studies to really work this out but then I say (b) Who wins?…who cares? we should not be wasting people’s brains on these agents, yes they work for some but on balance they don’t work for most people. Also what do you base you triumph on relapse rate progression, brain atrophy, etc.
COI. Multiple Non rlevant